Peter Davies, Phd

Biography

Peter Davies received a BSc and a PhD, both in Biochemistry from the University of Leeds, England. He was a post-doctoral fellow in the Department of Pharmacology at the University of Edinburgh, Scotland, before joining the staff of the Medical Research Council Brain Metabolism Unit in Edinburgh in 1974, where he began his research on Alzheimer’s disease. Dr. Davies’ early work was instrumental in the development of the currently approved drugs for Alzheimer’s disease — Aricept, Exelon and Razodyne. In 1977, he moved to Albert Einstein College of Medicine in the Bronx, NY, where he was a professor in the departments of pathology and neuroscience. Dr. Davies became the Scientific Director of the Litwin/Zucker Center for Research on Alzheimer’s Disease at Northwell Health’s Feinstein Institute for Medical Research in 2006. Peter Davies received a BSc and a PhD, both in Biochemistry from the University of Leeds, England. He was a post-doctoral fellow in the Department of Pharmacology at the University of Edinburgh, Scotland, before joining the staff of the Medical Research Council Brain Metabolism Unit in Edinburgh in 1974, where he began his research on Alzheimer’s disease. Dr. Davies’ early work was instrumental in the development of the currently approved drugs for Alzheimer’s disease — Aricept, Exelon and Razodyne. In 1977, he moved to Albert Einstein College of Medicine in the Bronx, NY, where he was a professor in the departments of pathology and neuroscience. Dr. Davies became the Scientific Director of the Litwin/Zucker Center for Research on Alzheimer’s Disease at Northwell Health’s Feinstein Institute for Medical Research in 2006.

Research Interest

The major goal of Dr. Davies’ research has been to improve our understanding of Alzheimer’s disease (AD) to allow for the discovery, development and testing of effective therapies. This research began in 1974 with investigation of neurotransmitter-related enzymes in the AD brain, and with the 1976 publication of evidence for a cholinergic deficit. The move to Albert Einstein College of Medicine in 1977 to join Dr. Robert Terry and Dr. Robert Katzman greatly broadened Dr. Davies’ training in neuroanatomy and neuropathology, and led to numerous publications that were increasingly aimed at understanding the cell biology of Alzheimer’s disease and related disorders. As a principal investigator on numerous National Institutes of Health (NIH) grants since 1979, Dr. Davies has had considerable experience in directing successful research programs. Always a collaborative researcher, he has participated in studies of Alzheimer’s disease over the years ranging from molecular genetics to clinical trials. The focus of these groups has been in the production, characterization and use of monoclonal antibodies, which are widely used in immunochemical and immunohistochemical studies of cell culture and animal models of Altzheimer’s disease, as well as in characterization of human neuropathology. They are produced largely to explore specific hypotheses regarding the signaling pathways that are inappropriately activated in the AD brain.